AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 0.6300 |
| Open | 0.6250 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.6048 - 1.3100 |
| 52 Week Range | 0.3500 - 3.2000 |
| Volume | 16,661,065 |
| Avg. Volume | 679,125 |
| Market Cap | 77.79M |
| Beta (3Y Monthly) | 2.00 |
| PE Ratio (TTM) | 12.73 |
| EPS (TTM) | 0.0550 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- PR Newswire•2 days ago
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares of common stock offered in the public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
- PR Newswire•2 days ago
Ampio Regulatory and Clinical Update
According to Michael Macaluso, Ampio CEO, "The Company has identified and engaged 15 clinical sites for the trial (AP-013) and patient identification is underway. This pivotal trial seeks to enroll approximately 1,000 patients, with an interim look, to allow sample size adjustments, if required.
- PR Newswire•25 days ago
Ampio Clinical, Regulatory and Corporate Update
Clinical: The results of the AP-003-C open label extension study outlining the safety and efficacy of repeat injections of Ampion™ in patients with severe osteoarthritis-of-the-knee (OAK) have been accepted as a podium presentation at the 83rd Annual Meeting of the Western Orthopedic Association (WOA) in Monterey, CA., held from July 31st to August 3rd, 2019. The WOA meeting was developed primarily for orthopedic and trauma surgeons and allied health professionals. The WOA Committee selected multiple research papers and invited nationally respected speakers to present practice-related techniques and findings in orthopedic surgery that cover a variety of specialty orthopedic disciplines and advances in treatment. The Ampion study is entitled "Investigating Repeated Intra-Articular Injections of The Anti-Inflammatory Compound LMWF-5A (Ampion) In Adults with Severe Osteoarthritis: An Open-Label Extension Study" and will be presented by orthopedic surgeon, John Schwappach, MD.
- PR Newswire•2 months ago
Ampio Pharmaceuticals Provides Regulatory Update
ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review.
- PR Newswire•3 months ago
Ampio Pharmaceuticals Provides Corporate Update
ENGLEWOOD, Colo., March 26, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that on March 11, 2019, the Company resubmitted a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a confirmatory Phase III clinical trial of its biological drug, Ampion™, for the treatment of patients afflicted with Osteoarthritis of the Knee (OAK). Mr. Macaluso, Ampio's CEO added, "After a series of interactions with the FDA, we believe we have addressed and answered all questions regarding trial design. The FDA confirmed they would respond to our SPA submission no later than April 25, 2019.
- PR Newswire•3 months ago
Ampio Updates Regulatory Status for Ampion
ENGLEWOOD, Colo., March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade 4 (KL 4) osteoarthritis of the knee (OAK) patients with concurrent controls that would be carried out under a Special Protocol Assessment (SPA). Ampio presented the FDA with two different forms of concurrent controls the company was considering in trial design: a saline injection or a sham injection, both previously identified by the FDA as possible controls.
- GlobeNewswire•4 months ago
Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•4 months ago
Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
ENGLEWOOD, Colo., Feb. 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a proposed trial design for the treatment of KL4 Osteoarthritis patients with Ampion™. Michael Macaluso, Ampio's CEO, explained: "A SPA is an agreement between the sponsor and FDA that the trial design, clinical endpoints, and statistical analyses could support marketing approval.
- PR Newswire•7 months ago
Ampio Updates Regulatory and Publication status for Ampion™
ENGLEWOOD, Colo., Nov. 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory and peer-review publication status of Ampion. Statisticians representing Ampio and the FDA met recently to discuss the clinical pathway of Ampion™, the company's lead drug, for the treatment of severe Osteoarthritis-of-the-knee (OAK). All KL-4 patients, from each single injection trial, were subjected to a statistical review that resulted in the FDA scheduling an additional, internal meeting that will include reviewers from the Office of Tissue and Advanced Therapies (OTAT).
- ACCESSWIRE•7 months ago
3 Health Care Stocks Rallying After US Midterms
/ Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.
- PR Newswire•7 months ago
Ampio Updates Regulatory and Clinical Status for Ampion™
ENGLEWOOD, Colo., Nov. 7, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK). Ampio designed what it thought would be a final pivotal clinical trial of Ampion (AP-003-C), predominately under guidance from FDA CBER's Office of Blood Research and Review (OBRR).
- GlobeNewswire•8 months ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
NEW YORK, Oct. 30, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE)..
- ACCESSWIRE•8 months ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
- ACCESSWIRE•8 months ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (AMPE) of the October 24, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Ampio stock or options between December 14, 2017 and August 7, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMPE. You can also contact us by calling Richard Gonnello toll free at877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
- ACCESSWIRE•8 months ago
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 22, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.
- ACCESSWIRE•8 months ago
2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.